Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial

Claudio Vernieri, Diego Signorelli, Giulia Galli, Monica Ganzinelli, Massimo Moro, Alessandra Fabbri, Elena Tamborini, Mirko Marabese, Elisa Caiola, Massimo Broggini, Lital Hollander, Rosaria Gallucci, Giulia Vandoni, Cecilia Gavazzi, Tiziana Triulzi, Mario Paolo Colombo, Angela Maria Rizzo, Paola Antonia Corsetto, Giancarlo Pruneri, Filippo de BraudGabriella Sozzi, Valter Torri, Marina Chiara Garassino

Research output: Contribution to journalArticle

Abstract

Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1)tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestrator of cancer cell metabolism, and halts tumor growth/proliferation during metabolic stress. Recent preclinical evidence suggests that LKB1-inactive lung adenocarcinoma is highly sensitive to metformin, a safe and low-cost antidiabetic compound that inhibits mitochondrial oxidative phosphorylation. The effects of metformin can be enhanced by nutrient deprivation (ie, glucose, amino acids), which reduces intracellular levels of ATP and anabolic precursors and can be achieved by the fasting mimicking diet (FMD). Noticeably, metformin also prevents resistance to cisplatin in preclinical in vitro and in vivo models of LKB1-inactive lung adenocarcinoma. Based on such preclinical evidence, the phase II FAME trial was designed to test the hypothesis that the addition of metformin, with or without cyclic FMD, to standard platinum-based chemotherapy improves the progression-free survival of patients with advanced, LKB-1 inactive lung adenocarcinoma. Enrolled patients will be randomized in a 1:1 ratio to receive cisplatin/carboplatin and pemetrexed with the addition of metformin alone (Arm A)or metformin plus FMD (Arm B). The FAME study will use a “pick-the-winner” design with the aim of establishing which of the 2 experimental treatments is superior in terms of antitumor efficacy and safety. The primary assumption of the study is that the combination of the 2 experimental treatments shall improve median progression-free survival from 7.6 months (historical data with chemotherapy alone)to 12 months. Secondary study endpoints are: objective response rate, overall survival, treatment tolerability, and compliance to the experimental treatment.

Original languageEnglish
Pages (from-to)e413-e417
JournalClinical Lung Cancer
Volume20
Issue number3
DOIs
Publication statusPublished - May 2019

Fingerprint

Pemetrexed
Metformin
Platinum
Fasting
Phosphotransferases
Diet
Drug Therapy
Liver
Cisplatin
Disease-Free Survival
Tumor Suppressor Proteins
Physiological Stress
Carboplatin
Oxidative Phosphorylation
Therapeutics
Hypoglycemic Agents
Adenocarcinoma of lung
Neoplasms
Survival Rate
Adenosine Triphosphate

Keywords

  • Cancer metabolism
  • LKB1 inactivation
  • Overall survival
  • Progression-free survival
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma : The FAME Trial. / Vernieri, Claudio; Signorelli, Diego; Galli, Giulia; Ganzinelli, Monica; Moro, Massimo; Fabbri, Alessandra; Tamborini, Elena; Marabese, Mirko; Caiola, Elisa; Broggini, Massimo; Hollander, Lital; Gallucci, Rosaria; Vandoni, Giulia; Gavazzi, Cecilia; Triulzi, Tiziana; Colombo, Mario Paolo; Rizzo, Angela Maria; Corsetto, Paola Antonia; Pruneri, Giancarlo; de Braud, Filippo; Sozzi, Gabriella; Torri, Valter; Garassino, Marina Chiara.

In: Clinical Lung Cancer, Vol. 20, No. 3, 05.2019, p. e413-e417.

Research output: Contribution to journalArticle

Vernieri, Claudio ; Signorelli, Diego ; Galli, Giulia ; Ganzinelli, Monica ; Moro, Massimo ; Fabbri, Alessandra ; Tamborini, Elena ; Marabese, Mirko ; Caiola, Elisa ; Broggini, Massimo ; Hollander, Lital ; Gallucci, Rosaria ; Vandoni, Giulia ; Gavazzi, Cecilia ; Triulzi, Tiziana ; Colombo, Mario Paolo ; Rizzo, Angela Maria ; Corsetto, Paola Antonia ; Pruneri, Giancarlo ; de Braud, Filippo ; Sozzi, Gabriella ; Torri, Valter ; Garassino, Marina Chiara. / Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma : The FAME Trial. In: Clinical Lung Cancer. 2019 ; Vol. 20, No. 3. pp. e413-e417.
@article{cefa02eafe4a48d5bcedd2e66111e95c,
title = "Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial",
abstract = "Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1)tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestrator of cancer cell metabolism, and halts tumor growth/proliferation during metabolic stress. Recent preclinical evidence suggests that LKB1-inactive lung adenocarcinoma is highly sensitive to metformin, a safe and low-cost antidiabetic compound that inhibits mitochondrial oxidative phosphorylation. The effects of metformin can be enhanced by nutrient deprivation (ie, glucose, amino acids), which reduces intracellular levels of ATP and anabolic precursors and can be achieved by the fasting mimicking diet (FMD). Noticeably, metformin also prevents resistance to cisplatin in preclinical in vitro and in vivo models of LKB1-inactive lung adenocarcinoma. Based on such preclinical evidence, the phase II FAME trial was designed to test the hypothesis that the addition of metformin, with or without cyclic FMD, to standard platinum-based chemotherapy improves the progression-free survival of patients with advanced, LKB-1 inactive lung adenocarcinoma. Enrolled patients will be randomized in a 1:1 ratio to receive cisplatin/carboplatin and pemetrexed with the addition of metformin alone (Arm A)or metformin plus FMD (Arm B). The FAME study will use a “pick-the-winner” design with the aim of establishing which of the 2 experimental treatments is superior in terms of antitumor efficacy and safety. The primary assumption of the study is that the combination of the 2 experimental treatments shall improve median progression-free survival from 7.6 months (historical data with chemotherapy alone)to 12 months. Secondary study endpoints are: objective response rate, overall survival, treatment tolerability, and compliance to the experimental treatment.",
keywords = "Cancer metabolism, LKB1 inactivation, Overall survival, Progression-free survival, Safety",
author = "Claudio Vernieri and Diego Signorelli and Giulia Galli and Monica Ganzinelli and Massimo Moro and Alessandra Fabbri and Elena Tamborini and Mirko Marabese and Elisa Caiola and Massimo Broggini and Lital Hollander and Rosaria Gallucci and Giulia Vandoni and Cecilia Gavazzi and Tiziana Triulzi and Colombo, {Mario Paolo} and Rizzo, {Angela Maria} and Corsetto, {Paola Antonia} and Giancarlo Pruneri and {de Braud}, Filippo and Gabriella Sozzi and Valter Torri and Garassino, {Marina Chiara}",
year = "2019",
month = "5",
doi = "10.1016/j.cllc.2018.12.011",
language = "English",
volume = "20",
pages = "e413--e417",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma

T2 - The FAME Trial

AU - Vernieri, Claudio

AU - Signorelli, Diego

AU - Galli, Giulia

AU - Ganzinelli, Monica

AU - Moro, Massimo

AU - Fabbri, Alessandra

AU - Tamborini, Elena

AU - Marabese, Mirko

AU - Caiola, Elisa

AU - Broggini, Massimo

AU - Hollander, Lital

AU - Gallucci, Rosaria

AU - Vandoni, Giulia

AU - Gavazzi, Cecilia

AU - Triulzi, Tiziana

AU - Colombo, Mario Paolo

AU - Rizzo, Angela Maria

AU - Corsetto, Paola Antonia

AU - Pruneri, Giancarlo

AU - de Braud, Filippo

AU - Sozzi, Gabriella

AU - Torri, Valter

AU - Garassino, Marina Chiara

PY - 2019/5

Y1 - 2019/5

N2 - Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1)tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestrator of cancer cell metabolism, and halts tumor growth/proliferation during metabolic stress. Recent preclinical evidence suggests that LKB1-inactive lung adenocarcinoma is highly sensitive to metformin, a safe and low-cost antidiabetic compound that inhibits mitochondrial oxidative phosphorylation. The effects of metformin can be enhanced by nutrient deprivation (ie, glucose, amino acids), which reduces intracellular levels of ATP and anabolic precursors and can be achieved by the fasting mimicking diet (FMD). Noticeably, metformin also prevents resistance to cisplatin in preclinical in vitro and in vivo models of LKB1-inactive lung adenocarcinoma. Based on such preclinical evidence, the phase II FAME trial was designed to test the hypothesis that the addition of metformin, with or without cyclic FMD, to standard platinum-based chemotherapy improves the progression-free survival of patients with advanced, LKB-1 inactive lung adenocarcinoma. Enrolled patients will be randomized in a 1:1 ratio to receive cisplatin/carboplatin and pemetrexed with the addition of metformin alone (Arm A)or metformin plus FMD (Arm B). The FAME study will use a “pick-the-winner” design with the aim of establishing which of the 2 experimental treatments is superior in terms of antitumor efficacy and safety. The primary assumption of the study is that the combination of the 2 experimental treatments shall improve median progression-free survival from 7.6 months (historical data with chemotherapy alone)to 12 months. Secondary study endpoints are: objective response rate, overall survival, treatment tolerability, and compliance to the experimental treatment.

AB - Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1)tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestrator of cancer cell metabolism, and halts tumor growth/proliferation during metabolic stress. Recent preclinical evidence suggests that LKB1-inactive lung adenocarcinoma is highly sensitive to metformin, a safe and low-cost antidiabetic compound that inhibits mitochondrial oxidative phosphorylation. The effects of metformin can be enhanced by nutrient deprivation (ie, glucose, amino acids), which reduces intracellular levels of ATP and anabolic precursors and can be achieved by the fasting mimicking diet (FMD). Noticeably, metformin also prevents resistance to cisplatin in preclinical in vitro and in vivo models of LKB1-inactive lung adenocarcinoma. Based on such preclinical evidence, the phase II FAME trial was designed to test the hypothesis that the addition of metformin, with or without cyclic FMD, to standard platinum-based chemotherapy improves the progression-free survival of patients with advanced, LKB-1 inactive lung adenocarcinoma. Enrolled patients will be randomized in a 1:1 ratio to receive cisplatin/carboplatin and pemetrexed with the addition of metformin alone (Arm A)or metformin plus FMD (Arm B). The FAME study will use a “pick-the-winner” design with the aim of establishing which of the 2 experimental treatments is superior in terms of antitumor efficacy and safety. The primary assumption of the study is that the combination of the 2 experimental treatments shall improve median progression-free survival from 7.6 months (historical data with chemotherapy alone)to 12 months. Secondary study endpoints are: objective response rate, overall survival, treatment tolerability, and compliance to the experimental treatment.

KW - Cancer metabolism

KW - LKB1 inactivation

KW - Overall survival

KW - Progression-free survival

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85059455131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059455131&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.12.011

DO - 10.1016/j.cllc.2018.12.011

M3 - Article

C2 - 30617039

AN - SCOPUS:85059455131

VL - 20

SP - e413-e417

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 3

ER -